Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR 1,094.10
-17.70 (-1.59%)
Jun 1, 2026, 3:29 PM IST
Strides Pharma Science Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 48,587 | 45,653 | 38,901 | 36,884 | 30,703 | |
Revenue Growth (YoY) | 6.43% | 17.36% | 5.47% | 20.13% | -7.41% |
Cost of Revenue | 19,587 | 21,285 | 19,109 | 17,580 | 16,136 |
Gross Profit | 29,000 | 24,369 | 19,793 | 19,304 | 14,566 |
Selling, General & Admin | 9,290 | 9,328 | 7,893 | 7,686 | 6,728 |
Other Operating Expenses | 10,457 | 7,025 | 6,154 | 7,746 | 7,881 |
Operating Expenses | 21,771 | 18,276 | 16,184 | 17,864 | 16,939 |
Operating Income | 7,229 | 6,093 | 3,609 | 1,439 | -2,373 |
Interest Expense | -1,785 | -2,074 | -2,385 | -2,176 | -1,457 |
Interest & Investment Income | - | 479.95 | 304.29 | 745.28 | 1,076 |
Earnings From Equity Investments | 4.69 | 18.37 | -539.67 | -2,853 | -1,108 |
Currency Exchange Gain (Loss) | - | 33.5 | 96.41 | 448.88 | -97.84 |
Other Non Operating Income (Expenses) | 1,507 | -368.89 | -357.45 | -345.98 | -239.31 |
EBT Excluding Unusual Items | 6,955 | 4,182 | 727.45 | -2,741 | -4,199 |
Merger & Restructuring Charges | -4.94 | 49.54 | -30.8 | 469.56 | -2,145 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.04 |
Gain (Loss) on Sale of Assets | - | 40.95 | 14.32 | 41.07 | 112.47 |
Asset Writedown | -34.7 | -0.05 | -1,575 | -330.4 | -46.76 |
Other Unusual Items | -228.79 | 597.12 | -283.83 | -301.08 | -246.06 |
Pretax Income | 6,687 | 4,869 | -1,148 | -2,862 | -6,525 |
Income Tax Expense | 941.66 | 775.16 | 291.12 | -553.01 | -1,783 |
Earnings From Continuing Operations | 5,745 | 4,094 | -1,439 | -2,309 | -4,743 |
Earnings From Discontinued Operations | - | 31,881 | 495.92 | 185.69 | - |
Net Income to Company | 5,745 | 35,975 | -943.12 | -2,123 | -4,743 |
Minority Interest in Earnings | -183.27 | -40.57 | 237 | 96.95 | 140.39 |
Net Income | 5,562 | 35,935 | -706.12 | -2,026 | -4,602 |
Net Income to Common | 5,562 | 35,935 | -706.12 | -2,026 | -4,602 |
Net Income Growth | -84.52% | - | - | - | - |
Shares Outstanding (Basic) | 92 | 92 | 91 | 90 | 90 |
Shares Outstanding (Diluted) | 92 | 92 | 91 | 90 | 90 |
Shares Change (YoY) | 0.17% | 1.12% | 1.02% | 0.37% | 0.04% |
EPS (Basic) | 60.34 | 390.55 | -7.76 | -22.49 | -51.28 |
EPS (Diluted) | 60.34 | 390.50 | -7.76 | -22.50 | -51.28 |
EPS Growth | -84.55% | - | - | - | - |
Free Cash Flow | 2,846 | 4,419 | 5,829 | -505.27 | -4,012 |
Free Cash Flow Per Share | 30.87 | 48.02 | 64.06 | -5.61 | -44.70 |
Dividend Per Share | 5.000 | 4.000 | 2.500 | 1.500 | - |
Dividend Growth | 25.00% | 60.00% | 66.67% | - | - |
Gross Margin | 59.69% | 53.38% | 50.88% | 52.34% | 47.44% |
Operating Margin | 14.88% | 13.35% | 9.28% | 3.90% | -7.73% |
Profit Margin | 11.45% | 78.71% | -1.81% | -5.49% | -14.99% |
Free Cash Flow Margin | 5.86% | 9.68% | 14.98% | -1.37% | -13.07% |
EBITDA | 9,253 | 7,688 | 5,371 | 3,403 | -494.5 |
EBITDA Margin | 19.04% | 16.84% | 13.81% | 9.23% | -1.61% |
D&A For EBITDA | 2,024 | 1,595 | 1,762 | 1,964 | 1,879 |
EBIT | 7,229 | 6,093 | 3,609 | 1,439 | -2,373 |
EBIT Margin | 14.88% | 13.35% | 9.28% | 3.90% | -7.73% |
Effective Tax Rate | 14.08% | 15.92% | - | - | - |
Revenue as Reported | 50,094 | 46,241 | 39,298 | 37,787 | 32,022 |
Advertising Expenses | - | 544.02 | 365.07 | 221.73 | 178.18 |